Cargando…

Incidence and Clinical Significance of De Novo Donor Specific Antibodies after Kidney Transplantation

Kidney transplantation has evolved over more than half a century and remarkable progress has been made in patient and graft outcomes. Despite these advances, chronic allograft dysfunction remains a major problem. Among other reasons, de novo formation of antibodies against donor human leukocyte anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lionaki, Sophia, Panagiotellis, Konstantinos, Iniotaki, Aliki, Boletis, John N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856119/ https://www.ncbi.nlm.nih.gov/pubmed/24348683 http://dx.doi.org/10.1155/2013/849835

Ejemplares similares

Kidney transplantation outcomes in patients with IgA nephropathy and other glomerular and non-glomerular primary diseases in the new era of immunosuppression
por: Lionaki, Sophia, et al.
Publicado: (2021)

Depletion of B Lymphocytes in Idiopathic Membranous Glomerulopathy: Results from Patients with Extended Follow-Up
por: Lionaki, Sophia, et al.
Publicado: (2013)

Characteristics and Clinical Significance of De Novo Donor-Specific Anti-HLA Antibodies after Kidney Transplantation
por: Jung, Hee-Yeon, et al.
Publicado: (2018)

The Influence of Antibodies against Angiotensin II Type-1 Receptor on the Outcome of Kidney Transplantation: A Single-Center Retrospective Study
por: Filiopoulos, Vassilis, et al.
Publicado: (2023)

Glomerular Diseases Associated with Malignancies: Histopathological Pattern and Association with Circulating Autoantibodies
por: Lionaki, Sophia, et al.
Publicado: (2020)

Clinical significance of de novo donor-specific antibody in kidney transplant recipients with chronic antibody-mediated rejection
por: Park, Woo Yeong, et al.
Publicado: (2021)

The natural history of de novo donor-specific HLA antibodies after kidney transplantation
por: López del Moral, Covadonga, et al.
Publicado: (2022)

Clinical Outcome of Kidney Transplant Recipients with C1q-Binding De Novo Donor Specific Antibodies: A Single-Center Experience
por: Marinaki, Smaragdi, et al.
Publicado: (2023)

A Meta-Analysis of the Safety and Efficacy of Maintenance Therapies for Antineutrophil Cytoplasmic Antibody Small-Vessel Vasculitis
por: Bellos, Ioannis, et al.
Publicado: (2022)

Primary Hepatic Burkitt Lymphoma in a Kidney Transplant Recipient
por: Lionaki, Sophia, et al.
Publicado: (2018)

Pathogenesis and Management of Acute Kidney Injury in Patients with Nephrotic Syndrome Due to Primary Glomerulopathies
por: Lionaki, Sophia, et al.
Publicado: (2019)

Importance and What to Watch Out for De Novo Donor Specific Anti-HLA Antibodies after Kidney Transplantation
por: Yang, Chul Woo
Publicado: (2018)

Low Serum C3 Pauci-Immune Glomerulonephritis: High Histopathological Activity and Lower Rates of Response to Standard Therapies
por: Lionaki, Sophia, et al.
Publicado: (2021)

Hypocomplementemia at Diagnosis of Antineutrophil Cytoplasmic Autoantibody Glomerulonephritis Is an Independent Risk Factor for a Worst Outcome
por: Lionaki, Sophia, et al.
Publicado: (2022)

IgM antibodies towards pre-endothelial cells: strong indication for an association with accelerated rejection. A case report
por: Kafetzi, Maria L., et al.
Publicado: (2011)

Occurrence of De novo Donor-Specific Antibodies After COVID-19 in Kidney Transplant Recipients Is Low Despite Immunosuppression Modulation
por: Masset, Christophe, et al.
Publicado: (2022)

Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoadsorption
por: Kälble, Florian, et al.
Publicado: (2021)

Association between longer hospitalization and development of de novo donor specific antibodies in simultaneous liver–kidney transplant recipients
por: Yazawa, Masahiko, et al.
Publicado: (2019)

Evaluation of Kidney Donor Risk Index/Kidney Donor Profile Index as Predictor Tools of Deceased-Donor Kidney Transplant Outcomes in a Greek Cohort
por: Darema, Maria, et al.
Publicado: (2023)

Plasma Exchange in ANCA-Associated Vasculitis: A Narrative Review
por: Tsiakas, Stathis, et al.
Publicado: (2021)

Clinical Significance of Shared T Cell Epitope Analysis in Early De Novo Donor-Specific Anti-HLA Antibody Production After Kidney Transplantation and Comparison With Shared B cell Epitope Analysis
por: Tomosugi, Toshihide, et al.
Publicado: (2021)

Impact of low‐level pretransplant donor‐specific antibodies on outcomes after kidney transplantation
por: Parajuli, Sandesh, et al.
Publicado: (2021)

Development of De Novo Donor Specific Antibodies Following COVID-19 Vaccination in Cardiac Transplant
por: Maybaum, S., et al.
Publicado: (2022)

Erratum: Clinical significance of shared T cell epitope analysis in early de novo donor-specific anti-HLA antibody production after kidney transplantation and comparison with shared B cell epitope analysis
Publicado: (2022)

Snowflake epitope matching correlates with child-specific antibodies during pregnancy and donor-specific antibodies after kidney transplantation
por: Niemann, Matthias, et al.
Publicado: (2022)

Circulating de novo Donor Specific Antibodies and Carotid Intima-media Thickness in Pediatric Kidney Transplant Recipients, A Pilot Study
por: Sgambat, Kristen, et al.
Publicado: (2020)

Safety and efficacy of eculizumab for the prevention of antibody‐mediated rejection after deceased‐donor kidney transplantation in patients with preformed donor‐specific antibodies
por: Glotz, Denis, et al.
Publicado: (2019)

De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients
por: Cioni, Michela, et al.
Publicado: (2017)

The incidence of cytomegalovirus infection after deceased-donor kidney transplantation from hepatitis-C antibody positive donors to hepatitis-C antibody negative recipients
por: Yazawa, Masahiko, et al.
Publicado: (2020)

Clinical significance of donor-specific anti-HLA-DR51/52/53 antibodies for antibody-mediated rejection in kidney transplant recipients
por: Park, Borae Geum, et al.
Publicado: (2019)

Desensitization using IVIG alone for living-donor kidney transplant: impact on donor-specific antibodies
por: Ulisses, Luiz Roberto de Sousa, et al.
Publicado: (2022)

Clinical significance of the presence of anti-human leukocyte antigen-donor specific antibody in kidney transplant recipients with allograft dysfunction
por: Chung, Byung Ha, et al.
Publicado: (2018)

The Various Forms of Nephrotic Syndrome in a Patient with Systemic Lupus Erythematosus
por: Lionaki, Sophia, et al.
Publicado: (2020)

Vitamin D Receptor Activity, Vitamin D Status, and Development of De-novo Donor-specific Antibody after Renal Transplantation
por: Mehrotra, Sonia, et al.
Publicado: (2020)

De Novo Donor Specific Antibody and Long-Term Outcome After Liver Transplantation: A Systematic Review and Meta-Analysis
por: Beyzaei, Zahra, et al.
Publicado: (2020)

Biopsy findings after detection of de novo donor-specific antibodies in renal transplant recipients: a single center experience
por: Waldecker, Christoph B., et al.
Publicado: (2021)

An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies
por: Prémaud, Aurélie, et al.
Publicado: (2017)

Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients
por: Kim, Hyung Woo, et al.
Publicado: (2023)

Low Incidence of Acute Antibody-Mediated Rejection after HLA Desensitization in Living Donor Kidney Transplant Recipients
por: Fernández Rivera, Constantino, et al.
Publicado: (2022)

Τhe Impact of Pre-Transplant Kidney Biopsy on the Evaluation of Prospective Living Kidney Donors
por: Marinaki, Smaragdi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gjgueibuo3it9vp41j48ts9b6h